Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTreatt Regulatory News (TET)

Share Price Information for Treatt (TET)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 461.50
Bid: 461.00
Ask: 463.00
Change: -1.00 (-0.22%)
Spread: 2.00 (0.434%)
Open: 464.00
High: 473.00
Low: 460.00
Prev. Close: 462.50
TET Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Treatt (TET): Sweet upgrades

19 May 2021 07:00

Edison Investment Research Limited Treatt (TET): Sweet upgrades 19-May-2021 / 07:00 GMT/BST


 

London, UK, 19 May 2021

 

Treatt (TET): Sweet upgrades

Treatt has once again demonstrated the strength of its business model, with another excellent set of results, and yet another upgrade to guidance. The performance continues to be testament to the management and culture of the business, which has been transformed under CEO Daemmon Reeve's nine years at the helm. Both sales and profit performance are impressive, and we once again raise our forecasts, as the 'healthier' categories continue to outperform. The relocation of the UK business is under way, and we expect the business to continue to perform well once the new UK capacity comes on stream.

 

Treatt trades at 40.7x and 28.1x FY21 P/E and EV/EBITDA, representing premiums of c 30% and c 40% respectively to its peers. We note that the current share price is discounting medium-term sales growth of 5.0%, falling to 2.5% in perpetuity, with a WACC of 5.7% and a terminal EBIT margin of 20.0%. We forecast net debt at end FY21, moving to a net cash position thereafter, and hence expect a significant uplift in the dividend in FY21.

Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Sara Welford +44 (0)20 3077 5700 consumer@edisongroup.com

Russell Pointon +44 (0)20 3077 5700 consumer@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group-/

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1198024 19-May-2021 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
3rd Sep 20075:52 pmRNSDirector/PDMR Shareholding
3rd Sep 20075:51 pmRNSDirector/PDMR Shareholding
28th Aug 20072:56 pmRNSDirector/PDMR Shareholding
2nd Aug 20074:56 pmRNSTrading Statement
21st May 20077:01 amRNSInterim Results
26th Feb 20077:01 amRNSEntry into organic market
22nd Dec 20069:09 amRNSAnnual Information Update
18th Dec 20064:51 pmRNSTotal Voting Rights
11th Dec 20067:01 amRNSFinal Results
17th Nov 20065:03 pmRNSDirector/PDMR Shareholding
17th Nov 20065:02 pmRNSNotice of Results
31st Jul 20062:38 pmRNSHolding(s) in Company
26th Jul 200611:33 amRNSHolding(s) in Company
22nd May 20067:00 amRNSInterim Results
15th May 20063:15 pmRNSNotice of Interim Results
11th May 20064:15 pmRNSAdoption of IFRS
29th Mar 20067:00 amRNSHolding(s) in Company
29th Mar 20067:00 amRNSHolding(s) in Company
18th Jan 20068:46 amRNSAnnual Information Update
12th Dec 20057:01 amRNSPreliminary Statement
4th Nov 20052:46 pmRNSNotice of Results
6th Sep 20059:36 amRNSBlocklisting Interim Review
6th Sep 20059:35 amRNSBlocklisting Interim Review
4th Aug 200510:32 amRNSDirectorate Change
9th Jun 20052:45 pmRNSHolding(s) in Company
8th Jun 20059:48 amRNSDirector Shareholding
31st May 20055:29 pmRNSHolding(s) in Company
27th May 200511:34 amRNSHolding(s) in Company
23rd May 20057:00 amRNSInterim Results
4th Mar 200511:10 amRNSBlocklisting Interim Review
4th Mar 200511:08 amRNSBlocklisting Interim Review
10th Feb 20055:29 pmRNSDirector Shareholding
31st Jan 200511:34 amRNSDirector Shareholding
28th Jan 200512:16 pmRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.